Predicted protein targets (top 11)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PNMT | P11086 | 5/20 | 0.44 |
| ▸ | ADRA2A | P08913 | 1/20 | 0.44 |
| ▸ | ADRA2B | P18089 | 1/20 | 0.44 |
| ▸ | ADRA2C | P18825 | 1/20 | 0.44 |
| ▸ | ASIC3 | Q9UHC3 | 1/20 | 0.44 |
| ▸ | CD44 | P16070 | 1/20 | 0.42 |
| ▸ | MAOB | P27338 | 1/20 | 0.42 |
| ▸ | DRD2 | P14416 | 2/20 | 0.42 |
| ▸ | DRD3 | P35462 | 2/20 | 0.42 |
| ▸ | GPR84 | Q9NQS5 | 1/20 | 0.41 |
| ▸ | AHR | P35869 | 1/20 | 0.40 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL30481091 | 1.00 | PNMT (0.44) | PNMTADRA2AADRA2BADRA2CASIC3 | |
| SCHEMBL6308292 | 1.00 | PNMT (0.44) | PNMTADRA2AADRA2BADRA2CASIC3 | |
| SCHEMBL5912311 | 0.90 | CYP2D6 (0.40) | PNMTADRA2AADRA2BADRA2CGPR84 | |
| SCHEMBL25405473 | 0.79 | ASIC3 (0.55) | PNMTASIC3CD44MAOBDRD2 | |
| SCHEMBL24086184 | 0.79 | GPR84 (0.48) | GPR84AHR | |
| SCHEMBL3247336 | 0.75 | PNMT (0.61) | PNMTADRA2AADRA2BADRA2CASIC3 | |
| 1,2,3,4-Tetrahydroisoquinoline SCHEMBL3328852 | 0.74 | PNMT (0.66) | PNMTADRA2AADRA2BADRA2CASIC3 | |
| SCHEMBL6186961 | 0.73 | DRD2 (0.43) | DRD2GPR84AHR | |
| SCHEMBL31269594 | 0.71 | HTR2C (0.40) | PNMTADRA2AADRA2BADRA2CASIC3 | |
| SCHEMBL24258510 | 0.70 | NPC1 (0.47) | PNMTADRA2AADRA2BADRA2CASIC3 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-6930185-B2 | Melanin-concentrating hormone antagonist | TAKEDA CHEMICAL INDUSTRIES, LTD. (JP) | 2005-08-16 | — | — | US | disclosed |
| US-20040077628-A1 | Melanin-concentrating hormone antagonist | TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) | 2004-04-22 | — | — | US | disclosed |
| EP-1285651-A1 | MELANIN CONCENTRATING HORMONE ANTAGONISTS | Takeda Chemical Industries, Ltd. (JP) | 2003-02-26 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20040077628-A1 | Melanin-concentrating hormone antagonist | MCHR1, MC1R, MCHR2 | PNMT 463/4885ADRA2A 223/4885ADRA2B 241/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.